Alnylam Pharmaceuticals Inc (ALNY)
150.41
-0.96
(-0.63%)
USD |
NASDAQ |
May 10, 16:00
151.04
+0.63
(+0.42%)
After-Hours: 20:00
Alnylam Pharmaceuticals Enterprise Value: 17.80B for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 09, 2024 | 17.80B |
May 08, 2024 | 17.91B |
May 07, 2024 | 18.17B |
May 06, 2024 | 17.78B |
May 03, 2024 | 17.92B |
May 02, 2024 | 17.66B |
May 01, 2024 | 17.62B |
April 30, 2024 | 16.86B |
April 29, 2024 | 17.29B |
April 26, 2024 | 16.78B |
April 25, 2024 | 16.82B |
April 24, 2024 | 16.84B |
April 23, 2024 | 17.12B |
April 22, 2024 | 17.09B |
April 19, 2024 | 16.91B |
April 18, 2024 | 17.01B |
April 17, 2024 | 17.03B |
April 16, 2024 | 17.21B |
April 15, 2024 | 17.33B |
April 12, 2024 | 17.43B |
April 11, 2024 | 17.88B |
April 10, 2024 | 17.92B |
April 09, 2024 | 18.37B |
April 08, 2024 | 18.38B |
April 05, 2024 | 18.07B |
Date | Value |
---|---|
April 04, 2024 | 17.81B |
April 03, 2024 | 17.72B |
April 02, 2024 | 17.75B |
April 01, 2024 | 18.04B |
March 31, 2024 | 17.55B |
March 28, 2024 | 17.48B |
March 27, 2024 | 18.10B |
March 26, 2024 | 17.80B |
March 25, 2024 | 17.81B |
March 22, 2024 | 17.11B |
March 21, 2024 | 17.05B |
March 20, 2024 | 17.22B |
March 19, 2024 | 17.24B |
March 18, 2024 | 17.15B |
March 15, 2024 | 17.38B |
March 14, 2024 | 17.29B |
March 13, 2024 | 17.27B |
March 12, 2024 | 17.05B |
March 11, 2024 | 17.36B |
March 08, 2024 | 17.45B |
March 07, 2024 | 17.46B |
March 06, 2024 | 17.43B |
March 05, 2024 | 17.43B |
March 04, 2024 | 17.48B |
March 01, 2024 | 17.80B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
5.802B
Minimum
May 20 2019
28.44B
Maximum
Dec 21 2022
17.18B
Average
17.19B
Median
Oct 29 2021
Enterprise Value Benchmarks
Ionis Pharmaceuticals Inc | 4.830B |
Pfizer Inc | 216.74B |
Blueprint Medicines Corp | 6.385B |
BridgeBio Pharma Inc | 6.587B |
Madrigal Pharmaceuticals Inc | 3.472B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -65.94M |
Revenue (Quarterly) | 494.33M |
Total Expenses (Quarterly) | 537.77M |
EPS Diluted (Quarterly) | -0.52 |
Gross Profit Margin (Quarterly) | 86.65% |
Profit Margin (Quarterly) | -13.34% |
Earnings Yield | -1.78% |
Normalized Earnings Yield | -1.423 |